{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T09:25:10Z","timestamp":1787131510650,"version":"build-2736575974"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004569","name":"Ministerstwo Edukacji i Nauki","doi-asserted-by":"publisher","award":["FSMG-2026-0018"],"award-info":[{"award-number":["FSMG-2026-0018"]}],"id":[{"id":"10.13039\/501100004569","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"publisher","award":["22-73-10141"],"award-info":[{"award-number":["22-73-10141"]}],"id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"publisher","award":["25-44-02059"],"award-info":[{"award-number":["25-44-02059"]}],"id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01-GM129325"],"award-info":[{"award-number":["R01-GM129325"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jconrel.2026.114679","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T16:30:10Z","timestamp":1770049810000},"page":"114679","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Genetically encoded self-assembling affibody-streptavidin nanoparticles for HER2-positive cancer theranostics"],"prefix":"10.1016","volume":"392","author":[{"given":"Anastasiia S.","family":"Obozina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna M.","family":"Iureva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandr A.","family":"Kotov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey M.","family":"Deyev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egor S.","family":"Korenkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria O.","family":"Shipunova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2026.114679_bb0005","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/nnano.2014.156","article-title":"Biocomputing based on particle disassembly","volume":"9","author":"Nikitin","year":"2014","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.jconrel.2026.114679_bb0010","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/s41551-020-0581-2","article-title":"Enhancement of the blood-circulation time and performance of nanomedicines via the forced clearance of erythrocytes","volume":"4","author":"Nikitin","year":"2020","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.jconrel.2026.114679_bb0015","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41416-024-02634-6","article-title":"Redefining cancer research for therapeutic breakthroughs","volume":"130","author":"Yuzhalin","year":"2024","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jconrel.2026.114679_bb0020","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1038\/s12276-022-00864-3","article-title":"Molecular targeted therapy for anticancer treatment","volume":"54","author":"Min","year":"2022","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.jconrel.2026.114679_bb0025","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1134\/S000629792403009X","article-title":"Human blood serum counteracts EGFR\/HER2-targeted drug lapatinib impact on squamous carcinoma SK-BR-3 cell growth and gene expression","volume":"89","author":"Shaban","year":"2024","journal-title":"Biochemistry (Mosc)"},{"key":"10.1016\/j.jconrel.2026.114679_bb0030","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2210562119","article-title":"Switchable targeting of solid tumors by BsCAR T cells","volume":"119","author":"Stepanov","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jconrel.2026.114679_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2024.151218","article-title":"Optimizing combination targeted immunotoxin therapy: insights from HER2 and EpCAM expression profiles","volume":"746","author":"Obozina","year":"2025","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jconrel.2026.114679_bb0040","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12943-025-02357-z","article-title":"Precision nanomedicine: navigating the tumor microenvironment for enhanced cancer immunotherapy and targeted drug delivery","volume":"24","author":"Sabit","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.jconrel.2026.114679_bb0045","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15010231","article-title":"Genetically encoded self-assembling protein nanoparticles for the targeted delivery in vitro and in vivo","volume":"15","author":"Obozina","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.114679_bb0050","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jconrel.2023.11.036","article-title":"Targosomes: anti-HER2 PLGA nanocarriers for bioimaging, chemotherapy and local photothermal treatment of tumors and remote metastases","volume":"365","author":"Komedchikova","year":"2024","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.114679_bb0055","doi-asserted-by":"crossref","first-page":"23087","DOI":"10.1039\/D3RA03369D","article-title":"Recent developments in natural biopolymer based drug delivery systems","volume":"13","author":"Fazal","year":"2023","journal-title":"RSC Adv."},{"key":"10.1016\/j.jconrel.2026.114679_bb0060","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","article-title":"Engineering precision nanoparticles for drug delivery","volume":"20","author":"Mitchell","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2026.114679_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.ohx.2024.e00554","article-title":"A do-it-yourself benchtop device for highly scalable flow synthesis of protein-based nanoparticles","volume":"19","author":"Korenkov","year":"2024","journal-title":"HardwareX"},{"key":"10.1016\/j.jconrel.2026.114679_bb0070","article-title":"Synthesis of nanoparticles using advanced techniques","volume":"8","author":"Vinukonda","year":"2025","journal-title":"Next Nanotechnol."},{"key":"10.1016\/j.jconrel.2026.114679_bb0075","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/s41551-021-00698-w","article-title":"The evolution of commercial drug delivery technologies","volume":"5","author":"Vargason","year":"2021","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.jconrel.2026.114679_bb0080","doi-asserted-by":"crossref","DOI":"10.3390\/molecules29030585","article-title":"The pharmaceutical industry in 2023: an analysis of FDA drug approvals from the perspective of molecules","volume":"29","author":"de La Torre","year":"2024","journal-title":"Molecules"},{"key":"10.1016\/j.jconrel.2026.114679_bb0085","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2026.114679_bb0090","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1021\/acs.molpharmaceut.1c00046","article-title":"The uniqueness of albumin as a carrier in nanodrug delivery","volume":"18","author":"Spada","year":"2021","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2026.114679_bb0095","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.7150\/thno.72594","article-title":"Antibody-based drug delivery systems for cancer therapy: mechanisms, challenges, and prospects","volume":"12","author":"Chen","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2026.114679_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2025.153018","article-title":"Challenges and opportunities beyond antibody-drug conjugates: toward a new era of programmable therapeutic proteins","volume":"794","author":"Kurtova","year":"2026","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jconrel.2026.114679_bb0105","article-title":"Genetically encoded in vivo ligation-driven targeted drug delivery system for oncotheranostics","author":"Obozina","year":"2025","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.jconrel.2026.114679_bb0110","article-title":"Self-assembling protein nanoparticles for cytosolic delivery of nucleic acids and proteins","author":"Eweje","year":"2025","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2026.114679_bb0115","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1038\/s41594-024-01288-5","article-title":"Computational design of non-porous pH-responsive antibody nanoparticles","volume":"31","author":"Yang","year":"2024","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.jconrel.2026.114679_bb0120","article-title":"Improved antitumor activity of TRAIL fusion protein via formation of self-assembling nanoparticle","volume":"7","author":"Huang","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2026.114679_bb0125","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1038\/s41467-023-37742-z","article-title":"Single-component multilayered self-assembling protein nanoparticles presenting glycan-trimmed uncleaved prefusion optimized envelope trimmers as HIV-1 vaccine candidates","volume":"14","author":"Zhang","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.114679_bb0130","doi-asserted-by":"crossref","first-page":"54","DOI":"10.32607\/actanaturae.11545","article-title":"Artificial scaffold polypeptides as an efficient tool for the targeted delivery of nanostructures in vitro and in vivo","volume":"14","author":"Shipunova","year":"2022","journal-title":"Acta Nat."},{"key":"10.1016\/j.jconrel.2026.114679_bb0135","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1134\/S1068162020060308","article-title":"Delivery of Barnase to cells in liposomes functionalized by Her2-specific DARPin module","volume":"46","author":"Shipunova","year":"2020","journal-title":"Russ. J. Bioorg. Chem."},{"key":"10.1016\/j.jconrel.2026.114679_bb0140","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/protein\/gzl004","article-title":"Rapid selection of specific MAP kinase-binders from designed ankyrin repeat protein libraries","volume":"19","author":"Amstutz","year":"2006","journal-title":"Protein Eng. Des. Sel."},{"key":"10.1016\/j.jconrel.2026.114679_bb0145","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0014-5793(03)00177-7","article-title":"A novel strategy to design binding molecules harnessing the modular nature of repeat proteins","volume":"539","author":"Forrer","year":"2003","journal-title":"FEBS Lett."},{"key":"10.1016\/j.jconrel.2026.114679_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e34211","article-title":"Albumin incorporation into recognising layer of HER2-specific magnetic nanoparticles as a tool for optimal targeting of the acidic tumor microenvironment","volume":"10","author":"Kolesnikova","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.jconrel.2026.114679_bb0155","doi-asserted-by":"crossref","first-page":"892","DOI":"10.2967\/jnumed.109.073239","article-title":"Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules","volume":"51","author":"Baum","year":"2010","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2026.114679_bb0160","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.2967\/jnumed.109.073346","article-title":"Targeting of HER2-expressing tumors using 111In-ABY-025, a second-generation affibody molecule with a fundamentally reengineered scaffold","volume":"51","author":"Ahlgren","year":"2010","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2026.114679_bb0165","doi-asserted-by":"crossref","first-page":"651","DOI":"10.2146\/ajhp110227","article-title":"Ecallantide for treatment of acute attacks of hereditary angioedema","volume":"69","author":"Martello","year":"2012","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.jconrel.2026.114679_bb0170","article-title":"Advances in the application of radionuclide-Labeled HER2 affibody for the diagnosis and treatment of ovarian cancer","volume":"12","author":"Hu","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jconrel.2026.114679_bb0175","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2967\/jnumed.120.248799","article-title":"Phase I study of 99mTc-ADAPT6, a scaffold protein-based probe for visualization of HER2 expression in breast cancer","volume":"62","author":"Bragina","year":"2021","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2026.114679_bb0180","doi-asserted-by":"crossref","first-page":"4858","DOI":"10.7150\/thno.86770","article-title":"Phase I clinical evaluation of 99mTc-labeled affibody molecule for imaging HER2 expression in breast cancer","volume":"13","author":"Bragina","year":"2023","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2026.114679_bb0185","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2209920","article-title":"Izokibep: preclinical development and first-in-human study of a novel IL-17A neutralizing affibody molecule in patients with plaque psoriasis","volume":"15","author":"Klint","year":"2023","journal-title":"MAbs"},{"key":"10.1016\/j.jconrel.2026.114679_bb0190","doi-asserted-by":"crossref","first-page":"7355","DOI":"10.1007\/s00253-019-10036-5","article-title":"Recent advances in the engineering and application of streptavidin-like molecules","volume":"103","author":"Le","year":"2019","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"10.1016\/j.jconrel.2026.114679_bb0195","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/php.12648","article-title":"Hybrid minimal core streptavidin-Obelin as a versatile reporter for bioluminescence-based bioassay","volume":"93","author":"Bashmakova","year":"2017","journal-title":"Photochem. Photobiol."},{"key":"10.1016\/j.jconrel.2026.114679_bb0200","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1021\/bc100081h","article-title":"Multimodality nuclear and fluorescence tumor imaging in mice using a streptavidin nanoparticle","volume":"21","author":"Liang","year":"2010","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2026.114679_bb0205","first-page":"3","article-title":"Streptavidin-biotin crosslinking of therapeutic enzymes with carrier antibodies: nanoconjugates for protection against endothelial oxidative stress","volume":"283","author":"Shuvaev","year":"2004","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.jconrel.2026.114679_bb0210","doi-asserted-by":"crossref","first-page":"12355","DOI":"10.1021\/ja505584f","article-title":"SpyAvidin hubs enable precise and ultrastable orthogonal nanoassembly","volume":"136","author":"Fairhead","year":"2014","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jconrel.2026.114679_bb0215","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1007\/s00259-009-1201-2","article-title":"Tumor delivery of antisense oligomer using trastuzumab within a streptavidin nanoparticle","volume":"36","author":"Wang","year":"2009","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.jconrel.2026.114679_bb0220","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","article-title":"Accurate structure prediction of biomolecular interactions with AlphaFold 3","volume":"630","author":"Abramson","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2026.114679_bb0225","doi-asserted-by":"crossref","DOI":"10.1002\/pro.4792","article-title":"Tools for structure building and analysis","volume":"32","author":"Meng","year":"2023","journal-title":"Protein Sci."},{"key":"10.1016\/j.jconrel.2026.114679_bb0230","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.jmb.2007.05.022","article-title":"Inference of macromolecular assemblies from crystalline state","volume":"372","author":"Krissinel","year":"2007","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.jconrel.2026.114679_bb0235","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15030833","article-title":"Targeted two-step delivery of oncotheranostic nano-PLGA for HER2-positive tumor imaging and therapy in vivo: improved effectiveness compared to one-step strategy","volume":"15","author":"Shipunova","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.114679_bb0240","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ijpharm.2007.03.036","article-title":"Preparation, characterisation and maintenance of drug efficacy of doxorubicin-loaded human serum albumin (HSA) nanoparticles","volume":"341","author":"Dreis","year":"2007","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2026.114679_bb0245","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ijpharm.2010.03.063","article-title":"Nanoparticles with dextran\/chitosan shell and BSA\/chitosan core--doxorubicin loading and delivery","volume":"393","author":"Qi","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2026.114679_bb0250","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1002\/cben.202300027","article-title":"Kinetic modeling to explain the release of medicine from drug delivery systems","volume":"10","author":"Askarizadeh","year":"2023","journal-title":"ChemBioEng Rev."},{"key":"10.1016\/j.jconrel.2026.114679_bb0255","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1158\/0008-5472.CAN-05-3521","article-title":"Tumor imaging using a picomolar affinity HER2 binding affibody molecule","volume":"66","author":"Orlova","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2026.114679_bb0260","doi-asserted-by":"crossref","first-page":"5397","DOI":"10.1039\/D0CS01127D","article-title":"Understanding nanoparticle endocytosis to improve targeting strategies in nanomedicine","volume":"50","author":"Sousa de Almeida","year":"2021","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.jconrel.2026.114679_bb0265","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2023.2239035","article-title":"Chemotherapy-induced neutropenia elicits metastasis formation in mice by promoting proliferation of disseminated tumor cells","volume":"12","author":"Russo","year":"2023","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jconrel.2026.114679_bb0270","doi-asserted-by":"crossref","first-page":"4","DOI":"10.4103\/sajc.sajc_439_18","article-title":"Incidence of febrile neutropenia with commonly used chemotherapy regimen in localized breast cancer","volume":"9","author":"Palukuri","year":"2020","journal-title":"South Asian J. Cancer"},{"key":"10.1016\/j.jconrel.2026.114679_bb0275","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/ame2.12139","article-title":"Clinical hematological and biochemical parameters in Swiss, BALB\/c, C57BL\/6 and B6D2F1 Mus musculus","volume":"3","author":"Silva-Santana","year":"2020","journal-title":"Animal Model. Exp. Med."},{"key":"10.1016\/j.jconrel.2026.114679_bb0280","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1200\/JCO.2018.77.9777","article-title":"Ado-trastuzumab emtansine for patients with HER2-mutant lung cancers: results from a phase II basket trial","volume":"36","author":"Li","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2026.114679_bb0285","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s10549-010-1090-x","article-title":"Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer","volume":"128","author":"Junttila","year":"2011","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.jconrel.2026.114679_bb0290","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1038\/s41591-024-03261-7","article-title":"Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b\/4 trial","volume":"30","author":"Harbeck","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2026.114679_bb0295","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1016\/j.ymthe.2023.03.019","article-title":"Clinical perspective: antibody-drug conjugates for the treatment of HER2-positive breast cancer","volume":"31","author":"Najminejad","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2026.114679_bb0300","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/cncr.34507","article-title":"Treatment-related adverse events of antibody-drug conjugates in clinical trials: a systematic review and meta-analysis","volume":"129","author":"Zhu","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.jconrel.2026.114679_bb0305","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15030713","article-title":"Mechanisms of ADC toxicity and strategies to increase ADC tolerability","volume":"15","author":"Nguyen","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jconrel.2026.114679_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2020.101506","article-title":"Antitumor efficacy and cardiotoxic effect of doxorubicin-loaded mixed micelles in 4T1 murine breast cancer model. Comparative studies using Doxil\u00ae and free doxorubicin","volume":"56","author":"Cagel","year":"2020","journal-title":"J. Drug Delivery Sci. Technol."},{"key":"10.1016\/j.jconrel.2026.114679_bb0315","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1158\/1078-0432.CCR-08-2392","article-title":"Tumor-targeted nanomedicines: enhanced antitumor efficacy in vivo of doxorubicin-loaded, long-circulating liposomes modified with cancer-specific monoclonal antibody","volume":"15","author":"ElBayoumi","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2026.114679_bb0320","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jconrel.2011.03.014","article-title":"Chloride channel-mediated brain glioma targeting of chlorotoxin-modified doxorubicine-loaded liposomes","volume":"152","author":"Xiang","year":"2011","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.114679_bb0325","doi-asserted-by":"crossref","first-page":"14900","DOI":"10.1073\/pnas.1407808111","article-title":"H-ferritin-nanocaged doxorubicin nanoparticles specifically target and kill tumors with a single-dose injection","volume":"111","author":"Liang","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jconrel.2026.114679_bb0330","doi-asserted-by":"crossref","first-page":"25080","DOI":"10.1038\/s41598-024-76851-7","article-title":"Anti-IL-1RAP scFv-mSA-S19-TAT fusion carrier as a multifunctional platform for versatile delivery of biotinylated payloads to myeloid leukemia cells","volume":"14","author":"Farokhi-Fard","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2026.114679_bb0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2024.129803","article-title":"In vivo-stable bis-iminobiotin for targeted radionuclide delivery with the mutant streptavidin","volume":"108","author":"Tatsumi","year":"2024","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.jconrel.2026.114679_bb0340","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clinbiochem.2019.08.012","article-title":"Best practices in mitigating the risk of biotin interference with laboratory testing","volume":"74","author":"Bowen","year":"2019","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.jconrel.2026.114679_bb0345","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1039\/D2CB00094F","article-title":"Protein scaffolds: antibody alternatives for cancer diagnosis and therapy","volume":"3","author":"Luo","year":"2022","journal-title":"RSC Chem. Biol."},{"key":"10.1016\/j.jconrel.2026.114679_bb0350","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2967\/jnumed.122.265364","article-title":"Human epidermal growth factor receptor 2-targeting 68GaGa-ABY-025 PET\/CT predicts early metabolic response in metastatic breast cancer","volume":"64","author":"Alhuseinalkhudhur","year":"2023","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2026.114679_bb0355","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1093\/bjd\/ljad186","article-title":"Izokibep for the treatment of moderate-to-severe plaque psoriasis: a phase II, randomized, placebo-controlled, double-blind, dose-finding multicentre study including long-term treatment","volume":"189","author":"Gerdes","year":"2023","journal-title":"Br. J. Dermatol."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926000805?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926000805?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T08:31:49Z","timestamp":1787128309000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365926000805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":71,"alternative-id":["S0168365926000805"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.114679","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetically encoded self-assembling affibody-streptavidin nanoparticles for HER2-positive cancer theranostics","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.114679","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114679"}}